PDE5A and early-onset autosomal dominant Alzheimer disease: PDE5 inhibitors are also gaining importance for treatment of neurodegenerative and neuropsychiatric disorders such as Alzheimer’s disease, epilepsy, stroke, depression and Huntington’s disease [69,70,71].